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Objectives This study sought to assess the determinants of platelet nitric oxide (NO) responsiveness in diabetic patients
admitted with acute coronary syndromes (ACS) and the short-term effects of aggressive glycemic control on
these factors.
Background Hyperglycemia is an independent risk factor for mortality in both diabetic patients and nondiabetic patients with
ACS. The mechanism(s) underlying this observation and potential benefit from its correction remain uncertain.
Although a reduction in NO bioavailability has been proposed, this remains untested in the ACS setting.
Methods A total of 76 diabetic patients with ACS were studied. Putative correlations between admission blood sugar level
(BSL), inhibition of platelet aggregation by the NO donor sodium nitroprusside (SNP), and superoxide (O2
) were
assessed. Hyperglycemic patients (n  60) were randomized to acute glycemic control with intravenous versus
subcutaneous insulin, and changes in the aforementioned parameters were compared. Plasma levels of the en-
dogenous inhibitor of NO synthase asymmetric dimethylarginine (ADMA) were also monitored.
Results There was an inverse correlation between admission BSL and both platelet SNP response (p  0.007) and
ADMA levels (p  0.045), and a positive correlation with O2
 generation (p  0.001). Intravenous insulin infu-
sion resulted in a greater reduction (p  0.001) in BSL, differentially improved platelet responsiveness to SNP
(p  0.049), and decreased O2
 (p  0.001) and ADMA levels (p  0.049).
Conclusions A component of platelet dysfunction in diabetic patients with ACS is impaired responsiveness to the anti-
aggregatory effects of NO, probably reflecting increased NO clearance by O2
. This phenomenon is reversed
by acute aggressive glycemic control. These findings provide a further rationale for use of insulin therapy in
acute myocardial infarction and suggest its extension to ACS patients. (J Am Coll Cardiol 2007;49:
304–10) © 2007 by the American College of Cardiology Foundation












aortality rates are significantly higher in diabetic patients
ho have an acute myocardial infarction (AMI) compared
ith nondiabetic patients (1,2), particularly in association
ith hyperglycemia (3,4). The mechanism(s) underlying
hese adverse outcomes remain uncertain.
One possible contributing factor is a reduction in nitric
xide (NO) bioavailability. In both animal (5) and human
6) diabetic studies, high glucose levels have been associated
ith a reduction in endothelium-dependent vasodilation.
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ccepted August 30, 2006.his may relate to an increase in oxidative stress and
ubsequent scavenging of NO (7,8) or an increase in
oncentration of the endogenous NO synthase (NOS)
nhibitor asymmetric dimethylarginine (ADMA) (9). These
nomalies are reversed in part by insulin therapy.
Glucose levels in diabetic patients not only affect vascular
eactivity, but also impact on platelet aggregability. Platelet-
ependent thrombus formation is increased in diabetic
atients with long-term poor glycemic control (10); con-
ersely, decreases in platelet aggregability have been re-
orted in association with improved diabetic control (11)
nd blood thrombogenicity (12). Moreover, an acute glu-
ose load is also associated with an increase in platelet
ctivation in type II diabetic patients (13), and a direct
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January 23, 2007:304–10 Glycemic Control and Platelet Functionlasma glucose level after an AMI (14). The pro-aggregant
ffects of hyperglycemia are also in part reversed by insulin.
he platelet–collagen interaction is inhibited by insulin
15), and in low doses these effects are mediated through
ncremental NO release (16); reversal of insulin’s anti-
ggregatory action occurs in the presence of NOS inhibition
17). Although NO is a physiologically important inhibitor
f platelet aggregation, its anti-aggregatory effects are im-
aired in stable and unstable angina pectoris (18,19). The
ossible interactions of glucose with this pathway, however,
emain uncertain.
Controversy continues to exist concerning the benefits of
ggressive control of hyperglycemia in patients with acute
oronary syndromes (ACS): even the results of studies in
MI (20,21) are less than completely conclusive regarding
hort-term beneficial effects. Furthermore, previously per-
ormed clinical studies in AMI shed little light on mecha-
ism(s) of putative clinical benefit. The current study was
herefore designed to examine the determinants of platelet
esponsiveness to NO in diabetic patients admitted with
CS and their possible modulation with short-term aggres-
ive glycemic control. We tested the null hypotheses that: 1)
dmission blood sugar level (BSL), and 2) correction of
yperglycemia were independent of platelet NO responsive-
ess and its principal biochemical correlates (18), O2

eneration and platelet cyclic guanosine-3=5=-mono-
hosphate (cGMP) formation. We also examined the pos-
ible impact of both admission BSL and correction of
yperglycemia on plasma ADMA levels.
ethods
eventy-six consecutive diabetic patients were enrolled in
he study. Patients were eligible for the study if they were
dmitted to the coronary care unit with a diagnosis of ACS
either unstable angina pectoris or non–Q-wave AMI) with
ither known diabetes mellitus or an admission BSL 11.1
mol/l. Criteria for exclusion were: 1) severe renal insuffi-
iency (serum creatinine 0.30 mmol/l), 2) concomitant
herapy with potent inhibitors of adenosine diphosphate
ADP)-induced platelet aggregation (clopidogrel and/or
lycoprotein IIb/IIIa inhibitors) and/or therapy with per-
exiline, which potentiates platelet NO responsiveness and
owers BSL (22).
Randomization regarding strategies for control of hyper-
lycemia was restricted to patients with admission BSL
etween 10 and 35 mmol/l. Patients randomized to aggres-
ive control had intravenous (IV) Actrapid (Novo Nordisk
harmaceuticals Pty Ltd., Copenhagen, Denmark) insulin
nfused according to the DIGAMI (Diabetes and Insulin-
lucose in Acute Myocardial Infarction) protocol (20)
ithout incremental glucose supplementation for the first
2 h after randomization; control patients were treated via a
ubcutaneous (SC) protocol, whereas no insulin was admin-
stered if a glucose reading was registered between 0 and 10
mol/l. With each subsequent 5-mmol/l increase in glu- uose, 4-U increments of insulin
ere administered. This was de-
ivered thrice daily with meals,
ith a maximum of 12 U of
nsulin given at one time.
Other anti-ischemic therapy
as initiated at the discretion of
he treating cardiologist. The
rotocol was approved by the
nstitutional Ethics of Human
esearch Committee of the local
nstitution, and informed con-
ent was obtained before study
ntry. Apart from monitoring of
arameters specifically associated with the study, all patients
nderwent continuous electrocardiogram monitoring using
GE-Marquette (Milwaukee, Wisconsin) 12-lead system
or the entire duration of the study to record episodes of
ignificant ST-segment depression. The occurrence of AMI
as defined on the basis of peak creatine kinase (CK) values
f 3 times the upper limit of normal. The CK values were
easured every 8 h for the first 24 h after admission and
ssayed via end-product absorption at 340 nm (Olympus
uto-analyzer, Kobe, Japan).
latelet studies. Blood sampling for platelet, O2
, and
GMP studies was performed at entry, and in randomized
atients was repeated after 12 h. Blood obtained from the
ntecubital vein was transferred slowly to plastic screw-top
ubes containing 1:10 volume of citric acid–sodium antico-
gulant (2 parts of 0.1 mol/l citric acid to 3 parts 0.1 mol/l
risodium citrate, pH 5). For platelet-rich plasma (PRP)
tudies, blood was centrifuged at 250 g for 10 min at room
emperature.
Platelet studies in whole blood (n  76) and PRP (n 
6) were performed as previously described (18,19) using a
ual-channel impedance lumi-aggregometer (model
60CA, Chrono-Log, Haverstown, Pennsylvania). Data
ere collected via a Chrono-Log model 810CA Aggro/link
omputer interface. To initiate aggregation experiments,
DP (1 mol/l) was added at the end of the incubation
eriod. Aggregation was monitored continually for 7 min
nd maximal responses recorded for electrical impedance,
easured in ohms. Inhibition of ADP-induced aggregation
y the NO donor sodium nitroprusside (SNP 10 mol/l),
dded 1 min before ADP, was expressed as a percentage of
esponse to ADP alone. The SNP was used in a previously
alidated concentration (18) as an index of platelet respon-
iveness to NO because unlike organic nitrates, it is a direct
O donor, and does not show cross-tolerance to nitroglyc-
rin (23).
hemiluminescence assay of O2
. Detection of O2
 in
hole blood was performed using a chemiluminescence
echnique (24), with lucigenin as a probe (n  63). A low
oncentration of lucigenin (12.5 mol/l) was used to min-
mize redox cycling. Chemiluminescence was monitored
Abbreviations
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infarction
BSL  blood sugar level
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own, Pennsylvania). Data were collected via a Chrono-log
odel 810CA Aggro/link computer interface. After 1 min,
he intensity of lucigenin-derived chemiluminescence
LDCL) was measured; results are expressed in millivolts.
latelet cGMP assay. Intraplatelet cGMP was measured
s previously described (25) from platelets harvested from
RP (n  36). Briefly, PRP was diluted 2-fold by 0.9%
aline and prewarmed at 37°C. If the final volume was 1
l, subsequent concentrations of SNP were appropriately
djusted. One minute before platelet harvest, 10 mol/l (or
quivalent) of SNP or normal saline control was added. The
RP was then filtered through GF/C glass microfiber filters
Whatman P/L, Brentford, United Kingdom) held by
lastic filter holders Swinnex-25 (Millipore Corp., Billerica,
assachusetts). Filters with absorbed platelets were rinsed
ith 0.9% saline and placed into 0.5 ml of 4 mmol/l
thylene diamine tetraacetic acid used to prevent cGMP
ecay. Tubes were then placed in a boiling water bath for 5
in. After this, samples were removed and centrifuged at
,000 g for 10 min. The cGMP concentration in the
upernatant was then assayed using a cGMP [125I] radio-
mmunoassay kit (Amersham, Buckinghamshire, United
ingdom). Results were expressed as an SNP-mediated
ercentage increase of cGMP levels.
DMA assay. The ADMA (NG,NG-dimethyl-L-arginine)
as extracted from plasma by strong cation exchange, derivat-
zed with 6-aminoquinolyl-N-hydroxysuccinimidyl carbam-
te (AccQ-Fluor, Waters, Australia) to produce a highly
table derivative and analyzed by high-performance liquid
hromatography (26). Recovery of ADMA from plasma was
92%, with intraassay and interassay variability of 2% and
%, respectively.
ther parameters examined. C-reactive protein (CRP)
evels (n  61) were determined with a high-sensitivity
RP assay (Beckman Immage Immunochemistry System,
ullerton, California). The non-esterified fatty acid
NEFA) test kit (Wako Pure Chemical Industries Ltd.,
saka, Japan) used an in vitro enzymatic colorimetric
ethod for the quantitation of NEFA or free fatty acids in
erum (n  61). Plasma glucose and creatine kinase values
ere derived via spectrophotometry. Glycated hemoglobin
as measured by high-performance liquid chromatography
Variant Haemoglobin A1C program, Bio-Rad Laborato-
ies, Hercules, California), and the insulin levels (n  50)
ere measured by an immunoassay kit (AxSym insulin,
bbott Laboratories, Abbott Park, Illinois) and expressed in
M/ml.
tatistical analysis and sample size calculation. Data
ere evaluated by the D’Agostino normality test for
aussian/non-Gaussian distribution: non-Gaussian distri-
utions were log transformed. Admission BSL values were
orrelated with platelet function and biochemistry using
inear regression with 95% confidence intervals (Excel 2003,
icrosoft, Seattle, Washington). We assessed the determi-ants of platelet NO response and blood O2
 content by a
tepwise multiple regression analysis (multivariate analysis).
For the intervention component of the study (intravenous
ersus subcutaneous insulin therapy in hyperglycemic pa-
ients), sample size calculation was based on preliminary
ata regarding SNP responsiveness in diabetic patients with
SL 10 mmol/l. On the assumption that in such patients
aseline SNP responses were normally distributed and had
alues at presentation of approximately 35  20%, a
andomized study with 30 patients in each group would
ave approximately 76% power to detect a 20% (1 SD)
elative change in SNP response at p  0.05; power to
etect 15% relative change was approximately 51%.
To assess the relative effects of IV versus SC insulin
herapy, a 2-way analysis of variance with repeated measures
as used. Statistical significance was assessed as p  0.05
nd is documented in relation to the interaction between
ime and therapy unless otherwise stated. All values are
xpressed as mean  SEM, with non-parametric data
xpressed as median values.
esults
haracteristics of all 76 patients studied are shown in Table
. Admission BSL was inversely correlated with platelet
esponsiveness to SNP in whole blood (r  0.31, p 
.007) (Fig. 1) but not in PRP. A significant correlation also
xisted between BSL and log LDCL (r  0.43, p  0.001)
Fig. 2), but not between BSL and SNP-mediated cGMP
ctivity. The majority (n  60) of patients had a BSL 10
mol/l. The oral hypoglycemic agents used included sulfo-
ylureas (n  34), biguanides (n  34), and thiazo-
idinediones (n  1). Irrespective of prior therapy, all
atients subsequently were treated with aspirin, heparin,
rganic nitrates (usually as intravenously infused nitroglyc-
rin), and oral anti-ischemic agents (beta-adrenoceptor or
on-dihydropyndine calcium antagonists).
dmission Baseline Characteristics (n  76)
Table 1 Admission Baseline Characteristics (n  76)
Age (yrs) 66 1.4
Gender (M:F) 49:27
Acute myocardial infarction (%) 29
Blood sugar level (mmol/l) 14.3 0.6 (range 5.1–31.7)




Cholesterol (mmol/l) 4.6 0.1
Diabetic medications (%)
None 32
Oral hypoglycemic agents 54
Insulin 14
Concomitant medications on admission (%)
Aspirin 50
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January 23, 2007:304–10 Glycemic Control and Platelet FunctionAdmission BSL also was positively correlated with log
RP (r  0.28, p  0.03), log neutrophil count (r 
.36, p  0.001), and log peak CK (r  0.37, p  0.001).
n inverse correlation existed between BSL and ADMA
r  0.27, p  0.045).
Parameters included in the stepwise multivariate anal-
sis of determinants of SNP response and O2
 content
ere: age, gender, BSL, statin therapy, insulin therapy,
ngiotensin-converting enzyme inhibitor therapy, and
K elevation. Admission BSL was a significant determinant
f O2
 generation (p  0.005) and an inverse determinant of
NP response (p 0.02), with increasing age also a significant
nverse determinant (p  0.03) of O2
 generation.
The baseline characteristics of the patients randomized
o 12 h of IV or SC insulin are shown in Table 2. The 2
roups were well matched regarding demographics and
harmacotherapy. As expected, IV insulin therapy was
ignificantly more effective in lowering BSL than SC
Figure 1 Relationship Between Platelet SNP Response
and Admission BSL (r  0.31, p  0.007)
BSL  blood sugar level; SNP  sodium nitroprusside.
Figure 2 Relationship Between Log Lucigenin-Derived LDCL
and Admission BSL (r  0.43, p < 0.001)
BSL  blood sugar level; LDCL  lucigenin-derived chemiluminescence.iherapy: BSL decreased from 16.9  0.9 mmol/l to 7.9 
.6 mmol/l in the IV group and 15.4  0.8 mmol/l to
0.5  0.8 mmol/l in the SC group (p  0.001).
nterestingly, insulin levels decreased to a similar extent
etween the 2 groups (p  0.38), from a median of 22.7
o 17 mol/ml in the IV group and 23.5 to 15 mol/ml
n the SC group.
Whole-blood platelet SNP response significantly im-
roved in the IV group compared with the SC group (p
0.049) (Fig. 3A), whereas O2
 generation was signif-
cantly reduced in the IV group compared with the SC
roup (p  0.001) (Fig. 3B). These changes occurred in
he absence of any significant fluctuation in cGMP
eneration, in aggregation responses to ADP, or any
hange in SNP response in PRP. Changes in plasma
DMA levels over the first 12 h of hypoglycemic therapy
re shown in Figure 3C. There was a differential reduc-
ion in ADMA levels in the IV insulin group compared
ith the SC insulin group (p  0.049).
Regarding other biochemical data, there was no sig-
ificant differential effect of treatment on NEFA levels in
atients randomized to receive IV insulin. The CRP
alues increased progressively with time (p  0.001)
ithout a differential effect according to treatment strat-
gy (median CRP increases, 0.4 and 5.0 mg/l for IV
nsulin and SC insulin, respectively).
iscussion
he effects of clinical strategies including insulin admin-
stration on outcome in patients with acute myocardial
haracteristics of Patients Randomized to Variabletr tegi s of Correction of Hyperglyc mia:ntravenou versus Subcutaneous Insulin Therapy
Table 2
Characteristics of Patients Randomized to Variable
Strategies of Correction of Hyperglycemia:





Age (yrs) 64 14 68 12
Gender (M:F) 20:10 17:13
Acute myocardial infarction (%) 38 32
Body mass index (kg/m2) 27.6 0.8 28.1 0.9
Blood sugar level (mmol/l) 16.9 0.9 15.4 0.8
Hemoglobin A1C (%) 9 2 8.5 1.6
Risk factors
Hypertension (%) 60 50
Smoking (%) 20 23
Cholesterol (mmol/l) 4.8 0.22 4.4 0.19
Diabetic treatment (%)
Diet 13 27




Angiotensin-converting enzyme inhibitor 47 27
Statin 33 33
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Glycemic Control and Platelet Function January 23, 2007:304–10ollow-up in the DIGAMI-1 study (20) showed that in
atients with evolving AMI, aggressive glycemic control
nitiated with an IV insulin infusion significantly reduced
ortality. Maintenance of normoglycemia using insulin
nfusion also has been shown to reduce mortality in
ntensive care patients (27), suggesting beneficial effects
n circumstances of increased oxidative stress. On the
ther hand, the results of the DIGAMI-2 study provide
o additional data to confirm these observations (21).
urthermore, the recently published results of the
REATE-ECLA (Clinical Trial of Reviparin and Met-
bolic Modulation in Acute Myocardial Infarction/
studios Cardiologicas Latin American Study Group)
28) indicate that in patients with evolving ST-segment
levation, AMI treatment with a combination of glucose,
nsulin, and potassium does not alter short-term mortal-
Figure 3 Differential Effects of IV and
SC Insulin Therapy on Changes Over 12 h
(A) Platelet sodium nitroprusside (SNP) response (p  0.049), (B) superoxide
generation (p  0.001), and (C) asymmetric dimethylarginine (ADMA) levels
(p  0.049). IV  intravenous; LDLC  lucigenin-derived chemiluminescence;
SC  subcutaneous.ty rates. The aforementioned important studies therefore naise 2 critical additional issues. First, does the putative
herapeutic impact of “metabolic” therapies such as insu-
in infusion primarily result from correction of hypergly-
emia (and this will be greatest in patients with the
oorest glycemic control), and second, what is the mech-
nism(s) underlying this effect?
This study is the first to evaluate NO responsiveness at
he platelet level in diabetic patients presenting with
CS. These results provide a basis for previous observa-
ions of adverse outcomes associated with hyperglycemia,
howing that admission BSL in this cohort is directly
orrelated with O2
 generation and inversely correlated
ith platelet NO responsiveness. Moreover, rapid cor-
ection of hyperglycemia by IV insulin infusion over 12 h
ncreases platelet responsiveness to NO while decreasing
2
 generation.
Glucose-stimulated increases in activity of nicotin-
mide adenine dinucleotide phosphate (NAD(P)H) oxi-
ase activity, the major source of O2
 release, have been
hown in both endothelial cells and neutrophils (29,30);
he difference between the whole-blood results and those
ith PRP may be related to more intense O2
 generation
n whole blood from neutrophil-derived NAD(P)H oxi-
ase.
At baseline, ADMA levels were inversely correlated with
SL. Consistent with this observation, Paiva et al. (31)
ound that ADMA levels in diabetic patients were inversely
orrelated with hemoglobin A1c. The inverse correlation
ith BSL may relate to enhanced renal excretion. Glomer-
lar filtration rate is increased in early diabetic kidney
isease and inversely correlates with ADMA levels (31).
evertheless, the finding that aggressive correction of hy-
erglycemia differentially and rapidly lowered ADMA levels
s consistent with the current understanding of the mecha-
isms controlling ADMA kinetics: ADMA is metabolized
y the enzyme dimethylarginine dimethylaminohydrolase,
hich is redox sensitive. In vitro studies have shown that
imethylarginine dimethylaminohydrolase activity is signif-
cantly impaired by in vitro high glucose levels, with
ubsequent increases in ADMA levels (9). Furthermore,
DMA levels correlated closely with LDCL. Available data
uggest that a reduction in plasma ADMA concentration on
he order of 10%, as observed in the current study, is likely
o be associated with improved NO synthase activity (32)
nd, if sustained, with improved outcomes (33).
The study has a number of limitations. First, vascular and
oronary endothelial function were not measured directly.
econd, the study’s findings that increased whole blood O2

orrelated with platelet hyporesponsiveness to NO and
hat rapid correction of hyperglycemia both decreased
2
 and restored platelet responsiveness to NO do not
rove a cause-and-effect relationship. Indeed, the corre-
ation between baseline BSL and platelet SNP response was
nly moderate, suggesting that other factors also modulate
NP responses. Furthermore, the results of this study are
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January 23, 2007:304–10 Glycemic Control and Platelet Functionyocardial infarction (and thus to the majority of patients
n DIGAMI-1 [20]) or to nondiabetic patients treated with
lucose, insulin, and potassium regimens (27). Although we
ecently have shown that platelet hyporesponsiveness to NO
s an independent predictor of incremental long-term car-
iac morbidity and mortality (34), the current study did not
ddress long-term outcomes, nor was it sized to detect
ifferences in short-term event rates. It has also been shown
ecently (35) that high glucose concentrations decrease
latelet NO production and diminish the anti-aggregatory
ffects of aspirin. Furthermore, the effects of insulin admin-
stration include activation of platelet NO synthase (36). It
s possible that the observed effects of a high BSL might
ave been modulated to some extent by these processes,
lthough SNP responsiveness is, in theory, independent of
ndogenous NO production.
The major findings of the current study also provide a
hysiological and biochemical rationale for urgent reversal
f hyperglycemia in diabetic patients admitted with ACS.
n doing so, the results suggest that the benefits of insulin
herapy in ischemic diabetic patients may be largely inde-
endent of changes in myocardial metabolism; thus it would
e expected that patients at risk for ongoing ischemia
articularly would benefit from such therapy.
cknowledgments
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